Showing 654 results

Filters Content type: News, Editors' picks, About HIV Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

Access to healthcare

How India's Patent Office Destroyed Gilead's Global Game Plan

Editor's pick
Bloomberg Businessweek
19 January 2015
New & experimental hepatitis C treatment

Merck speeds up drug-submission plans for hep C, lung cancer

Editor's pick
Reuters
13 January 2015
The search for a cure

New open-access journal in the rapidly developing field of virus eradication

Editor's pick
Mediscript
23 December 2014
New & experimental hepatitis C treatment

US FDA approves AbbVie hepatitis C drug, costs $83319 for 12 weeks

Editor's pick
Reuters
20 December 2014
New & experimental hepatitis C treatment

Daclatasvir for hepatitis C: added benefit not proven

Editor's pick
German Institute for Quality and Efficiency in Health Care (IQWiG)
11 December 2014
New & experimental hepatitis C treatment

Sofosbuvir/ledipasvir cures most previously treated hepatitis C patients with cirrhosis

News
10 December 2014
Hepatitis C treatment

Sofosbuvir/ledipasvir with ribavirin cures most people with hepatitis C recurrence after liver transplantation

News
2 December 2014
Hepatitis C treatment

Sofosbuvir + simeprevir shows good results for hepatitis C in real-world use

News
2 December 2014
New & experimental hepatitis C treatment

FDA declines to approve Bristol-Myers hepatitis drug

Editor's pick
Reuters
27 November 2014
Hepatitis C treatment

AbbVie 3D regimen cures recurrent HCV in most liver transplant recipients without cirrhosis

News
27 November 2014
Hepatitis C transmission & prevention

"Promising" results in Oxford trials of Hepatitis C vaccine

Editor's pick
Cherwell
26 November 2014
Hepatitis C treatment

Daclatasvir + sofosbuvir demonstrates good cure rate for genotype 3 hepatitis C

News
25 November 2014
New & experimental hepatitis C treatment

CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe

Editor's pick
AbbVie press release
21 November 2014
Hepatitis C treatment

AbbVie 3D regimen and sofosbuvir/ribavirin show high cure rates for HCV in people with HIV co-infection

News
21 November 2014
New & experimental hepatitis C treatment

Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients

News
19 November 2014
Hepatitis C treatment

NHS asks Nice to delay ground-breaking hepatitis C drug

Editor's pick
Channel 4 News (blog)
19 November 2014
New & experimental hepatitis C treatment

European Commission Grants Marketing Authorization for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir)

Editor's pick
Gilead press release
19 November 2014
Hepatitis C treatment

Merck's grazoprevir/elbasvir combo shows high cure rates, including for people with cirrhosis and HIV/HCV co-infection

News
13 November 2014
Hepatitis C treatment

Sofosbuvir/ledipasvir and AbbVie 2D regimen cure most people with HCV genotype 4

News
13 November 2014
Hepatitis C treatment

Sofosbuvir/ledipasvir with ribavirin is highly effective for people with decompensated cirrhosis

News
12 November 2014
New & experimental hepatitis C treatment

Daclatasvir TRIO regimen has good cure rates for hepatitis C patients with or without cirrhosis

News
11 November 2014
Hepatitis C treatment

New HCV drugs pass muster in real world

Editor's pick
MedPage Today
11 November 2014
New & experimental hepatitis C treatment

New pill that can cure hepatitis C approved for patients in Scotland

Editor's pick
STV
11 November 2014
New & experimental hepatitis C treatment

Merck’s four-week treatment for hepatitis C misses the mark

Editor's pick
Wall Street Journal
11 November 2014